Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Track ELTX with free AI briefings, catalyst countdowns, and dilution alerts.

ELTX · Elicio Therapeutics, Inc.

Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.

On the Downside Radar: financing pressure. About 10.0 months of cash at its recent burn rate (Sep 30, 2026 balance sheet), an at-the-market (ATM) program filed Mar 16, 2026, and no offering in the last 90 days. Of biotech stocks in this setup with 6 to 12 months of cash, 35% sold new shares within three months and 67% were lower 60 trading days later (median -12%). How we know
$30.9M Cash on Hand
10mo Cash Runway
Follow ELTX by email Get an email when ELTX reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.

We send one confirmation email first. Only emails about ELTX, unsubscribe in one click. Privacy

📣 What ELTX Says Is Next

Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.

📄 Latest SEC Filings in Plain English

Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.

🧪 Trial & FDA Catalysts

📊 Drug Pipeline

DrugIndicationMost advanced trialStatus
AMP KRAS Vaccine ELI-002 Pancreatic Ductal Adenocarcinoma Phase 1/2 · NCT05726864 Active not recruiting
mFOLFIRINOX Pancreatic Cancer Phase 1 · NCT07671339 Recruiting

Also used in these trials (approved or third-party drugs, not ELTX's own candidates): Tislelizumab.

Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it

💰 Cash Runway & Dilution Risk

ELTX holds $30.9M in cash and short-term investments (as of Sep 30, 2026) and burns about $9.3M/quarter from operations, an estimated runway of 10 months at that rate (BioRadar estimate, not company guidance).

Dilution pressure: 90 · High

Recent financing filings on SEC EDGAR:

Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when ELTX files for a raise →

👥 Who Owns ELTX

Insiders 35.9% Other 5%+ holders 9.3% Institutions (96 holders) 22.6% Public and other holders 32.2%
HolderTypeShares% of sharesAs of
Yekaterina Chudnovsky
Director, 10% owner · +136,975 options
Insider 9,764,864 34.50% 2025-06-03
Moti Investments LLC 5%+ holder (13G) 1,408,892 4.98% 2026-07-01
Knoll Capital Management, LLC 5%+ holder (13G) 1,211,957 4.28% 2026-07-01
Jay Venkatesan
Director · +133,750 options
Insider 180,534 0.64% 2024-11-26
Robert Connelly
CEO, President and Director, Director · +455,744 options
Insider 120,570 0.43% 2026-02-02
Christopher Haqq
Executive Vice President, Head of R&D an · +159,543 options
Insider 57,381 0.20% 2026-02-02
Preetam Shah
Chief Strategy and Financial Officer · +300,357 options
Insider 24,000 0.08% 2026-02-02
Peter DeMuth
Chief Scientific Officer · +138,832 options
Insider 21,543 0.08% 2026-02-02

Share count 28,307,225 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.

Get the full ELTX picture

The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for ELTX and every other ticker you follow. Card required, cancel anytime.

Start 7-day free trial →

Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.